



NIH Clinical Research on Hepatocellular Carcinoma and Biliary Tract Carcinoma

For More Information

NIH Clinical Center

Office of Patient Recruitment

800-411-1222

TTY: 800-877-8339

Se habla español

Email: PRPL@cc.nih.gov

Online: <https://go.usa.gov/xpEKb>

NIH Study: 16-C-0135

*The NIH Clinical Center, America's Research Hospital
is located on the Metro red line (Medical Center)
in Bethesda, Maryland.*

Researchers at the National Institutes of Health (NIH) in Bethesda, Maryland are investigating if durvalumab given in combination with tremelimumab can help patients diagnosed with Hepatocellular Carcinoma (HCC) or advanced biliary tract carcinoma (BTC) that has not responded to standard treatment. The results of this study may provide answers for a new treatment that may help patients with hepatocellular carcinoma or advanced biliary tract carcinoma for which standard treatment has not help.

STUDY DESIGN:

- Will receive a biopsy of the tumor.
- Will receive therapy divided into cycles, each lasting 28 days.
- Patients will receive only Durvalumab after their 4th therapy cycle.